These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27799019)

  • 21. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
    Robinson DG; Gallego JA; John M; Petrides G; Hassoun Y; Zhang JP; Lopez L; Braga RJ; Sevy SM; Addington J; Kellner CH; Tohen M; Naraine M; Bennett N; Greenberg J; Lencz T; Correll CU; Kane JM; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1227-36. PubMed ID: 26338693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
    Lasser RA; Mao L; Gharabawi G
    Schizophr Res; 2004 Feb; 66(2-3):163-7. PubMed ID: 15061249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.
    Paslakis G; Deuschle M; Thome J; Rüsse S; Kopf D
    Pharmacopsychiatry; 2012 May; 45(3):96-9. PubMed ID: 22174030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
    Robinson DG; Woerner MG; Napolitano B; Patel RC; Sevy SM; Gunduz-Bruce H; Soto-Perello JM; Mendelowitz A; Khadivi A; Miller R; McCormack J; Lorell BS; Lesser ML; Schooler NR; Kane JM
    Am J Psychiatry; 2006 Dec; 163(12):2096-102. PubMed ID: 17151160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia.
    Glynn SM; Marder SR; Liberman RP; Blair K; Wirshing WC; Wirshing DA; Ross D; Mintz J
    Am J Psychiatry; 2002 May; 159(5):829-37. PubMed ID: 11986138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.
    Citrome L; Casey DE; Daniel DG; Wozniak P; Kochan LD; Tracy KA
    Psychiatr Serv; 2004 Mar; 55(3):290-4. PubMed ID: 15001730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
    Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
    Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Watanabe K; Mimura M; Uchida H
    J Clin Psychiatry; 2014 Nov; 75(11):1209-14. PubMed ID: 25099201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
    Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
    J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
    Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
    Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
    Boettger S; Jenewein J; Breitbart W
    Palliat Support Care; 2015 Aug; 13(4):1079-85. PubMed ID: 25191793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individual placement and support for individuals with recent-onset schizophrenia: integrating supported education and supported employment.
    Nuechterlein KH; Subotnik KL; Turner LR; Ventura J; Becker DR; Drake RE
    Psychiatr Rehabil J; 2008; 31(4):340-9. PubMed ID: 18407884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.
    Keks NA; Ingham M; Khan A; Karcher K
    Br J Psychiatry; 2007 Aug; 191():131-9. PubMed ID: 17666497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.